ASTRO 2024
ASTRO 2024
Advertisement
Rebecca AraujoASTRO 2024 | October 15, 2024
Guideline-concordant androgen deprivation therapy is associated with a survival benefit in high-risk prostate cancer.
Read More
Rebecca AraujoASTRO 2024 | October 14, 2024
Patients who underwent radical prostatectomy also had a higher likelihood of decision regret.
Tamara ThomasASTRO 2024 | October 10, 2024
People of color had an average delay of 6 months from symptom onset to diagnosis of young-onset colorectal cancer.
Tamara ThomasASTRO 2024 | October 9, 2024
Both Fluciclovine and PSMA PET/CT guided radiation therapy would significantly change pre-PET radiation therapy volumes.
Tamara ThomasASTRO 2024 | October 10, 2024
P-CARE integrates genetics, family history, and ancestry to offer a more objective risk assessment.
Tamara ThomasASTRO 2024 | October 8, 2024
After 10 years, 3.3% of patients who were recurrence-free developed distant metastasis.
Tamara ThomasASTRO 2024 | October 3, 2024
High-risk genomic classifiers were associated with a 10-fold higher risk of prostate cancer.
Tamara ThomasASTRO 2024 | October 3, 2024
The use of gender-affirming hormone therapy was associated with lower PSA levels compared with cisgender men.
Tamara ThomasASTRO 2024 | October 2, 2024
MRI guidance helps to reduce the amount of healthy tissue targeted during radiation therapy for prostate cancer.
Tamara ThomasASTRO 2024 | October 2, 2024
Advanced radiotherapy using fewer, stronger doses delivered similar quality-of-life outcomes and side effects.
Advertisement
Advertisement
Advertisement
Latest News

October 15, 2024